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Aspirin, β-blockers, angiotensin-converting enzyme inhibitors,
and statins have each been shown to improve the outcome
of patients with coronary artery disease. The benefit of
each of these drugs is generally pervasive, spanning a wide
spectrum of patients. However, we might not have been
aggressive enough in exploring the limits of the benefits
that these treatments confer. One gap in the extensive clin-
ical trial evidence supporting the use of these therapies is
that statins have never been tested in patients with acute
coronary syndromes. There is compelling evidence that
statins reduce coronary events in the setting of both
primary and secondary prevention. However, patients were
excluded from previous secondary prevention trials with
statins if they had experienced myocardial infarction or
unstable angina within the preceding 3–6 months.
This ‘knowledge gap’ has perhaps contributed to a ‘treat-
ment gap’. Although it is clear that patients who have suf-
fered an acute coronary event would obtain long-term
benefit from cholesterol-lowering therapy, it continues to
be the last thing that physicians do [1]. The focus tends to
settle on mechanical therapies to relieve flow-limiting
stenoses or antiplatelet and antithrombotic drugs that
reduce recurrent events over the short term. Most patients
leave hospital after an acute coronary event without
receiving a statin or any other cholesterol-lowering drug. In
fact, only 31.7% of 138,001 patients discharged from
1470 hospitals in the USA during a recent 12-month
period received a cholesterol-lowering drug [2].
Recent evidence suggests that lowering low-density
lipoprotein (LDL)-cholesterol favorably influences patho-
physiological mechanisms that may be intimately involved
in the genesis of acute coronary syndromes [3–5]. Inten-
sive LDL-cholesterol reduction has the potential to improve
endothelial function within hours [3] by reducing the pro-
duction of superoxide anion within the vessel wall, thus
facilitating the release of nitric oxide and slowing its rate of
catabolism. Cholesterol lowering also normalizes the ten-
dency to increase the deposition of platelet thrombus, a
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feature of hypercholesterolemia [4]. A third important con-
sequence of cholesterol lowering is a decrease in inflam-
mation at the sites of atherosclerotic lesions, resulting in a
decrease in circulating inflammatory markers [5]. The
MIRACL trial tested whether or not these mechanisms
have clinical relevance.
Results of MIRACL
At 122 sites in 19 countries, 3086 patients with unsta-
ble angina or non-Q-wave infarction were randomized to
placebo or to atorvastatin (80 mg/day) within
24–96 hours of admission to hospital [6,7]. The main
exclusion criteria were planned revascularization, a total
cholesterol level greater than 270 mg/dl, or a contraindi-
cation to statin therapy. There was no lower limit for
either total cholesterol or LDL-cholesterol. The mean
LDL-cholesterol level on treatment was 135 mg/dl in the
placebo group and 72 mg/dl in the atorvastatin group.
The primary, predefined endpoint was the time to death,
myocardial infarction, resuscitated cardiac arrest, or
worsening angina with new objective evidence of
myocardial ischemia requiring urgent rehospitalization.
This composite endpoint was reduced from 17.4% to
14.8%, a relative reduction of 16% (P = 0.048).
Although each of the components of the primary end-
point was reduced, most of the benefit was derived from
a 26% relative decrease in worsening angina with objec-
tive evidence of myocardial ischemia requiring urgent
rehospitalization (P = 0.02). Stroke, a secondary end-
point, was reduced by 50%, from 1.6% to 0.8%, with
atorvastatin (P = 0.045).
In contrast to the previous major primary and secondary
prevention trials with statins, in which the duration of
follow-up was at least 4–5 years, the duration of treatment
in the MIRACL trial was 4 months. A second important
feature of the trial was that it tested the effects of a statin
at the time when coronary events are highest: soon after
an episode of unstable angina or non-Q-wave infarction.
The short duration of therapy and high event rate during
this interval combine to make this treatment extremely
cost-effective. For approximately $500 in drug costs per
patient, the event rate during 4 months of treatment was
reduced by 2.6%, a cost:benefit ratio that compared favor-
ably with that seen in long-term secondary prevention with
statins [8]. This difference of 2.6% in absolute event rates
corresponds to a number needed to treat to prevent one
event in approximately 38.
Like all innovative clinical trials, MIRACL raises many inter-
esting questions, some of which will be discussed here.
Would benefit extend to all patients with
acute coronary syndromes?
Patients with Q-wave infarction were excluded from
MIRACL because many of the events that they experience
during follow-up are the result of left ventricular dysfunc-
tion or ventricular arrhythmias, processes that are unlikely
to be influenced by a lowering of cholesterol level.
However, it seems reasonable to expect that the reduction
in recurrent ischemic events observed in MIRACL would
also extend to this population.
Patients scheduled to undergo revascularization were
also excluded from the trial, on the presumption that coro-
nary events related to initial and recurrent procedures
might obscure any treatment effect. Revascularization is a
focal strategy, whereas atherosclerosis is a diffuse arterial
disease, and statin therapy has potential benefit through-
out the entire arterial system. Many recurrent ischemic
events (both coronary and cerebrovascular) result from
instability at sites other than the original causal coronary
lesion. Therefore, the benefits of revascularization and
intensive lipid-lowering treatment would be expected to
be complementary.
Is event reduction related to LDL-cholesterol
lowering?
In previous primary and secondary prevention trials with
statins, the investigators correlated the degree of benefit
to baseline lipid levels and to the change in lipid levels
with treatment. This approach is unlikely to be fruitful in
MIRACL for several reasons: (1) baseline lipid measure-
ments might have been transiently depressed owing to
the acute coronary event; (2) lipid levels during treatment
were first measured at 6 weeks, by which time many of
the endpoint events had already occurred; (3) factors
other than serum lipids have a greater effect on acute
coronary syndromes than on stable coronary disease; and
(4) the statistical power for subgroup analyses is low
because the treatment effect was barely statistically sig-
nificant for the whole trial.
Notwithstanding these limitations, there was no trend to
suggest that atorvastatin treatment in MIRACL was of
greater benefit in patients with higher baseline LDL-
cholesterol levels. It is therefore reasonable to apply the
MIRACL strategy irrespective of serum lipid determina-
tions at the time of the acute coronary event.
In MIRACL, LDL-cholesterol levels during treatment dif-
fered by 52% between the placebo and atorvastatin
groups. Would a lower dose of atorvastatin, or of any
other statin, have produced the same degree of benefit?
Answering this question conclusively would require a
study in which patients with acute coronary syndromes
were randomly assigned to receive these different thera-
pies. In previous long-term cholesterol-lowering trials,
involving different patient populations and different treat-
ments, the reduction of acute coronary events was propor-
tional to the degree of LDL-cholesterol reduction with
active treatment [9].
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Why was the treatment effect different for
different endpoints?
The reductions in total mortality and in myocardial infarc-
tion were much smaller than the reductions in worsening
angina with objective evidence or in stroke, and were not
statistically significant. The trial was not powered to show
a reduction in these individual endpoints, and the 95%
confidence intervals for each of the four components of
the primary composite endpoint overlapped broadly.
MIRACL should be interpreted as showing a reduction in
the composite endpoint rather than just in one or more of
the components. Combining these endpoints is reason-
able because they have, at least in part, a common patho-
physiological basis and might all be expected to respond
in the same way to treatment.
Do other trials test the effect of statins in
acute coronary syndromes?
At least three other clinical trials that are currently under
way will expand our knowledge of the effects of statins
early after an acute coronary event. The Aggrastat to Zocor
(A to Z) Trial includes an initial phase in which patients with
unstable angina or myocardial infarction without ST-
segment elevation are all treated with tirofiban and are ran-
domized to enoxaparin or unfractionated heparin. Stabilized
patients, including patients with ST-elevation myocardial
infarction not included in the original randomization, are
then randomized to either simvastatin (40 mg/day) or
placebo. After 1 month the dose of simvastatin is increased
to 80 mg/day; after 4 months, patients in the placebo arm
begin taking simvastatin at 20 mg/day. The projected
enrollment for the second phase of the trial is 4500
patients. Follow-up will continue until the occurrence of
970 endpoint events, defined as cardiac death, myocardial
infarction, or readmission for an acute coronary syndrome.
The Prevention of Re-Infarction by Early Treatment of
Cerivastatin Study (PRINCESS) will randomize 3000
patients with acute myocardial infarction within 48 hours
of admission to receive either a placebo or 0.4 mg/day
cerivastatin. At 3 months the dose will be increased to
0.8 mg/day and the placebo patients will begin taking
0.4 mg/day cerivastatin. The primary endpoint is a com-
posite of fatal or nonfatal myocardial infarction, unstable
angina, heart failure or cardiac death. A minimum follow-up
period of 2 years is planned.
The Pravastatin or Atorvastatin Evaluation and Infection
Therapy (PROVE IT) Trial will randomize 4000 patients up
to 10 days after an acute coronary syndrome to pravas-
tatin (40 mg/day) or atorvastatin (80 mg/day), with a mean
follow-up of 2 years. Patients with total cholesterol levels
of 240 mg/dl or more will be excluded. Patients will also
be randomized to the antibiotic gatifloxacin or to placebo,
to determine whether antibiotics reduce recurrent coro-
nary events.
Are there observational data on the use of
statins in acute coronary syndromes?
Recent observational studies indicate that patients who
are treated with a statin early after a coronary event
have a much more favorable outcome than those who
are not [10–12].
A prospective cohort study using data from the Register
of Information and Knowledge about Swedish Heart
Intensive care Admissions (RIKS-HIA) showed that early
initiation of treatment with statin in patients with acute
myocardial infarction was associated with a reduced
1-year mortality [10]. The study compared 5528 patients
who received statins at or before hospital discharge with
14,071 who did not. At 1 year, mortality was 4.0% in
statin users and 9.3% in non-users. This difference nar-
rowed considerably after adjustment for confounding
factors. However, early treatment with statin was still
associated with a reduction in 1-year mortality, with a rel-
ative risk of 0.75 (95% confidence intervals 0.63–0.89,
P = 0.001).
Retrospective analyses of clinical trial databases of
patients with acute coronary syndromes have also shown
this pattern. A report examining the 20,809 patients in the
Global Use of Strategies to Open Occluded Coronary
Arteries in Acute Coronary Syndromes (GUSTO IIb) and
Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor
Suppression Using Integrilin Therapy (PURSUIT) trials,
who were discharged from hospital after an acute coro-
nary syndrome, revealed that those treated with a lipid-
lowering drug exhibited a survival advantage that was
already apparent at 1 month [11]. The adjusted risk ratio
for 6-month mortality was 0.67 (95% confidence intervals
0.48–0.95, P = 0.023). Similarly, in a preliminary report
from Orbofiban in Patients with Unstable coronary Syn-
dromes – Thrombolysis in Myocardial Infarction (OPUS-
TIMI 16), mortality at 1 month was reduced in patients
treated with lipid-lowering drugs (94% of which were
statins) compared with those who were not: 0.7% versus
2.4% (P < 0.001) [12].
In each of these three observational studies, patients
who were treated with lipid-lowering drugs were younger
and healthier than patients who were not given this treat-
ment. The apparent benefit from early statin therapy
decreased in each population after adjustment for vari-
ables known to affect prognosis. Physicians are probably
much less likely to prescribe statins after an acute coro-
nary event in patients perceived to have a poor progno-
sis. This selection bias might account for not just a part
but for all of the apparent benefit observed with statin
use in these three studies. As in other situations, ran-
domized trials of statin therapy, started early after an
acute coronary event, are necessary to determine
whether this approach has merit.
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How should MIRACL influence clinical
practice?
Taken together with the evidence from previous secondary
prevention trials, MIRACL should convince even the most
stubborn that treatment of unstable angina and non-Q-wave
infarction should include a statin, should begin in the hospi-
tal, and should be given irrespective of baseline LDL-choles-
terol levels. One dose of one statin was tested in MIRACL.
Whether similar benefit would accrue from smaller dosages
or with other statins will in part be answered by the other
trials of statins in acute coronary syndromes.
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